Bicycle Therapeutics PLC Sponsored ADR $BCYC Shares Acquired by Tybourne Capital Management HK Ltd.

Tybourne Capital Management HK Ltd. boosted its position in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 72.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 993,743 shares of the company’s stock after purchasing an additional 417,400 shares during the period. Bicycle Therapeutics makes up 20.0% of Tybourne Capital Management HK Ltd.’s portfolio, making the stock its 3rd biggest position. Tybourne Capital Management HK Ltd.’s holdings in Bicycle Therapeutics were worth $6,907,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in BCYC. Long Focus Capital Management LLC grew its holdings in Bicycle Therapeutics by 138.2% during the 1st quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock valued at $10,984,000 after purchasing an additional 750,661 shares in the last quarter. Armistice Capital LLC grew its holdings in Bicycle Therapeutics by 21.7% during the 1st quarter. Armistice Capital LLC now owns 2,672,000 shares of the company’s stock valued at $22,685,000 after purchasing an additional 476,000 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in Bicycle Therapeutics during the 1st quarter valued at $3,471,000. Woodline Partners LP bought a new position in Bicycle Therapeutics during the 1st quarter valued at $3,088,000. Finally, Millennium Management LLC boosted its stake in Bicycle Therapeutics by 156.5% during the 1st quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock valued at $3,850,000 after acquiring an additional 276,671 shares during the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $7.88 on Monday. The firm’s 50-day moving average is $7.55 and its 200-day moving average is $7.83. Bicycle Therapeutics PLC Sponsored ADR has a 1 year low of $6.10 and a 1 year high of $25.77. The company has a market cap of $546.16 million, a P/E ratio of -2.25 and a beta of 1.47.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.The business had revenue of $2.90 million during the quarter, compared to the consensus estimate of $9.43 million. As a group, sell-side analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current year.

Insider Activity

In other news, CEO Kevin Lee sold 3,231 shares of the firm’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the transaction, the chief executive officer directly owned 475,310 shares in the company, valued at approximately $3,997,357.10. This trade represents a 0.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 8,527 shares of company stock valued at $71,738. Company insiders own 8.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Morgan Stanley reduced their price objective on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicycle Therapeutics in a research note on Tuesday, October 14th. Oppenheimer reiterated an “outperform” rating and set a $44.00 price objective (down from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. JMP Securities reduced their price objective on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Finally, Royal Bank Of Canada set a $27.00 price objective on shares of Bicycle Therapeutics and gave the company an “outperform” rating in a research note on Monday, August 11th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.22.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.